» Articles » PMID: 18041935

Overview of Parkinson's Disease

Overview
Journal Pharmacotherapy
Specialty Pharmacology
Date 2007 Nov 29
PMID 18041935
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

This overview of Parkinson's disease is designed to serve as a background to the discussion elsewhere in this supplement on the pharmacotherapy used in its management. Parkinson's disease is a common progressive neurodegenerative condition associated with significant disability and negative impact on quality of life. Although the cause of Parkinson's disease is unknown, the pathologic manifestation involves the loss or dysfunction of dopaminergic neurons in the substantia nigra pars compacta. Characteristic clinical manifestations include difficulty with coordinated movement such as asymmetric resting tremor, rigidity, and bradykinesia. These symptoms and their response to levodopa constitute the basis for a clinical diagnosis of Parkinson's disease. Postural instability and gait abnormalities occur in more advanced disease. Although there is no cure for Parkinson's disease, a number of pharmacologic treatments are available for managing the motor and nonmotor symptoms. Research is under way to assess the disease-modifying ability of both standard and newer treatments.

Citing Articles

Eye Tracking as Biomarker Compared to Neuropsychological Tests in Parkinson Syndromes: An Exploratory Pilot Study Before and After Deep Transcranial Magnetic Stimulation.

Cont C, Stute N, Galli A, Schulte C, Wojtecki L Brain Sci. 2025; 15(2).

PMID: 40002513 PMC: 11852570. DOI: 10.3390/brainsci15020180.


Epigallocatechin-3-Gallate, Quercetin, and Kaempferol for Treatment of Parkinson's Disease Through Prevention of Gut Dysbiosis and Attenuation of Multiple Molecular Mechanisms of Pathogenesis.

Kalu A, Ray S Brain Sci. 2025; 15(2).

PMID: 40002477 PMC: 11853474. DOI: 10.3390/brainsci15020144.


Impaired Mitochondrial Function and Ubiquitin Proteasome System Activate α-Synuclein Aggregation in Zinc-Induced Neurotoxicity: Effect of Antioxidants.

Singh G, Mittra N, Singh C J Mol Neurosci. 2025; 75(1):16.

PMID: 39907853 DOI: 10.1007/s12031-024-02293-5.


The Role of Virtual Reality in Postural Rehabilitation for Patients with Parkinson's Disease: A Scoping Review.

Agostini F, Conti M, Morone G, Iudicelli G, Fisicaro A, Savina A Brain Sci. 2025; 15(1.

PMID: 39851391 PMC: 11764033. DOI: 10.3390/brainsci15010023.


Using resting-state functional magnetic resonance imaging and contrastive learning to explore changes in the Parkinson's disease brain network and correlations with gait impairment.

An R, Dong L, Zhang M, Wang S, Yan Y, Wang Z Quant Imaging Med Surg. 2025; 15(1):608-622.

PMID: 39839056 PMC: 11744164. DOI: 10.21037/qims-24-1227.